Abnormal response to the anorexic effect of GHS-R inhibitors and exenatide in male Snord116 deletion mouse model for Prader-Willi syndrome

Endocrinology

Volumn 155, Issue 7, 2014, Pages 2355-2362

  Lin, Dahe ^a,c   Wang, Qi ^a   Ran, Haiying ^a   Liu, Kai ^a   Wang, Yao ^a   Wang, Juanjuan ^a   Liu, Yazhen ^a   Chen, Ruichuan ^a   Sun, Yuxiang ^b   Liu, Runzhong ^a   Ding, Feng ^a  

^a XIAMEN UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c PUTIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GHRELIN; GHRELIN RECEPTOR; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; FOOD INTAKE; GENOTYPE; GLUCOSE BLOOD LEVEL; HYPERPHAGIA; MALE; MOUSE; NONHUMAN; PRADER WILLI SYNDROME; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; ANOREXIA; DISEASE MODELS, ANIMAL; EATING; FASTING; GHRELIN; HUMANS; HYPERPHAGIA; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGOPEPTIDES; PEPTIDES; PIPERIDINES; PRADER-WILLI SYNDROME; QUINAZOLINONES; RECEPTORS, GHRELIN; RNA, SMALL NUCLEOLAR; SUBSTANCE P; VENOMS;

EID: 84903289212     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-2083     Document Type: Article

References (49)

1. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14(1):10-26.
2. Hoffman CJ, Aultman D, Pipes P. A nutrition survey of and recommendations for individuals with Prader-Willi syndrome who live in group homes. J Am Diet Assoc. 1992;92(7):823-830, 833.
3. Stevenson DA, Heinemann J, Angulo M, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2007;45(2):272-274. (Pubitemid 47220543)
4. Motaghedi R, Lipman EG, Hogg JE, Christos PJ, Vogiatzi MG, Angulo MA. Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. Eur J Med Genet. 2011;54(1):14-18.
5. Gallagher RC, Pils B, Albalwi M, Francke U. Evidence for the role of PWCR1/HBII-85 C/D box small nucleolar RNAs in Prader-Willi syndrome. Am J Hum Genet. 2002;71(3):669-678. (Pubitemid 34970140)
6. Schule B, Albalwi M, Northrop E, et al. Molecular breakpoint cloning and gene expression studies of a novel translocation t(4;15)(q27; q11.2) associated with Prader-Willi syndrome. BMC Med Genet. 2005;6:18.
7. de Smith AJ, Purmann C, Walters RG, et al. Adeletion of the HBII-85 class of small nucleolar RNAs (snoRNAs) is associated with hyperphagia, obesity and hypogonadism. Hum Mol Genet. 2009; 18(17):3257-3265.
8. Duker AL, Ballif BC, Bawle EV, et al. Paternally inherited microdeletion at 15q11.2 confirms a significant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur J Hum Genet. 2010;18(11):1196-1201.
9. Sahoo T, del Gaudio D, German JR, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet. 2008;40(6):719-721. (Pubitemid 351748873)
10. Ding F, Li HH, Zhang S, et al. SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deficiency and hyperphagia in mice. PLoS One. 2008;3(3):e1709.
11. Skryabin BV, Gubar LV, Seeger B, et al. Deletion of the MBII-85 snoRNA gene cluster in mice results in postnatal growth retardation. PLoS Genet. 2007;3(12):e235.
12. Kojima M, Kangawa K. Ghrelin: from gene to physiological function. Results Probl Cell Differ. 2010;50:185-205.
13. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med. 2002;8(7):643-644. (Pubitemid 34778697)
14. DelParigi A, Tschop M, Heiman ML, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in prader-willi syndrome. J Clin Endocrinol Metab. 2002;87(12):5461-5464. (Pubitemid 36034344)
15. Haqq AM, Farooqi IS, O'Rahilly S, et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(1):174-178. (Pubitemid 36115161)
16. De Waele K, Ishkanian SL, Bogarin R, et al. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur J Endocrinol. 2008;159(4):381-388.
17. Haqq AM, Stadler DD, Rosenfeld RG, et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(8): 3573-3576. (Pubitemid 37034497)
18. Tan TM, Vanderpump M, Khoo B, et al. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2004;89(8): 4162-4165. (Pubitemid 39071530)
19. Asakawa A, Inui A, Kaga T, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut. 2003;52(7): 947-952. (Pubitemid 36765284)
20. Chopin LK, Seim I, Walpole CM, Herington AC. The ghrelin axis-does it have an appetite for cancer progression? Endocrine Rev. 2012;33(6):849-891.
21. Perez-Tilve D, Gonzalez-Matias L, Alvarez-Crespo M, et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes. 2007;56(1):143-151.
22. Seetho IW, Jones G, Thomson GA, Fernando DJ. Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res Clin Pract. 2011;92(1):e1-2.
23. Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, Malecki MT. Liraglutide therapy in Prader-Willi syndrome. Diabet Med. 2011; 28(6):755-756.
24. Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr J. 2012.
25. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obesity research. 1998;6(1):47-53. (Pubitemid 128679644)
26. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol. 2003;23(22):7973-7981. (Pubitemid 37377491)
27. Sun Y, Butte NF, Garcia JM, Smith RG. Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance. Endocrinology. 2008;149(2):843-850. (Pubitemid 351159337)
28. Tschop MH, Speakman JR, Arch JR, et al. A guide to analysis of mouse energy metabolism. Nat Methods. 2012;9(1):57-63.
29. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor-identification of a potent inverse agonist. Mol Endocrinol. 2003;17(11):2201-2210. (Pubitemid 37352532)
30. Maletinska L, Matyskova R, Maixnerova J, et al. The peptidic GHS-R antagonist [D-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of post-menopausal obesity. Mol Cell Endocrinol. 2011;343(1-2):55-62.
31. Depoortere I, Thijs T, Peeters T. The contractile effect of the ghrelin receptor antagonist, D-Lys3-GHRP-6, in rat fundic strips is mediated through 5-HT receptors. Eur J Pharmacol. 2006;537(1-3): 160-165.
32. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005;65(7):2738-2745. (Pubitemid 40490075)
33. Esler WP, Rudolph J, Claus TH, et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology. 2007;148(11):5175-5185. (Pubitemid 350012622)
34. Gharib WH, Robinson-Rechavi M. When orthologs diverge between human and mouse. Briefings Bioinform. 2011;12(5):436-441.
35. Liao BY, Zhang J. Null mutations in human and mouse orthologs frequently result in different phenotypes. Proc Natl Acad Sci USA. 2008;105(19):6987-6992. (Pubitemid 351754517)
36. Gould TD, Gottesman, II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav. 2006;5(2): 113-119. (Pubitemid 43344963)
37. Hoffman KL. Role of murine models in psychiatric illness drug discovery: a dimensional view. Expert Opin Drug Discov. 2013;8(7): 865-877.
38. Sze L, Purtell L, Jenkins A, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2011;96(8): E1314-1319.
39. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes. 2009;58(12):2820-2827.
40. Mack CM, Moore CX, Jodka CM, et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond). 2006;30(9):1332-1340. (Pubitemid 44306514)
41. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43(1):173-181. (Pubitemid 43733604)
42. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology. 2000;141(6):1936-1941. (Pubitemid 32274340)
43. Young AA, Gedulin BR, Bhavsar S, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999;48(5):1026-1034. (Pubitemid 29226349)
44. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
45. He M, Guan N, Gao WW, et al. A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities. Acta Pharmacologica Sinica. 2012;33(2):148-154.
46. Purtell L, Sze L, Loughnan G, et al. In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. Neuropeptides. 2011; 45(4):301-307.
47. Lee S, Walker CL, Wevrick R. Prader-Willi syndrome transcripts are expressed in phenotypically significant regions of the developing mouse brain. Gene Exp Pattern. 2003;3(5):599-609. (Pubitemid 37074913)
48. Zhang Q, Bouma GJ, McClellan K, Tobet S. Hypothalamic expression of snoRNA Snord116 is consistent with a link to the hyperphagia and obesity symptoms of Prader-Willi syndrome. Int J Dev Neruosci. 2012;30(6):479-485.
49. Ding F, Li HH, Li J, Myers RM, Francke U. Neonatal maternal deprivation response and developmental changes in gene expression revealed by hypothalamic gene expression profiling in mice. PLoS One. 2010;5(2):e9402.